Manuka Inc. (MNKA)

[funnyG986]

INKS Huge big board connection! Nasdaq Co Oramed Pharmaceuticals President owns 25% of the OS

8K on Aug 30, 2016 showing merger with Artemis Therapeutics completed. Go to Page 20 and find
POST-MERGER BENEFICIAL OWNERSHIP OF THE COMPANY’S COMMON STOCK
http://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=11569818

Tonak LTD owns 17M common out of 69M OS after the merger (24.44%). It also owns 1747 shares of series B.
"Consists of 17,047,500 shares of common stock beneficially owned by Tonak Ltd. Mr. Nadav Kidron is the natural person with voting and dispositive power over our securities held by Tonak Ltd. Does not include 1,747.03 shares of Series B Preferred Stock exercisable into 126,980,868 shares of Common Stock."

Who's Mr. Nadav Kidron, the controlling person here? Google it!


The first result showing Mr. Nadav Kidron IS the President of Nasdaq company Oramed Pharmaceuticals Inc.

Management - Oramed Pharmaceuticals
www.oramed.com/about-us/management/
Mar 2, 2016 - Nadav Kidron, Esq. Chief Executive Officer, President & Director. Mr. Kidron serves as Chief Executive Officer & Director of Oramed ...
http://www.oramed.com/about-us/management/


Nadav Kidron's Biography
Mr. Nadav Kidron was appointed President, Chief Executive Officer and director in March 2006. He is also a director of Israel Advanced Technology Industries organization and of Artemis Therapeutics and until 2016 was a director of Entera Bio Ltd. In 2009, he was a fellow at the Merage Foundation for U.S.-Israel Trade Programs for executives in the life sciences field. From 2003 to 2006, he was the managing director of the Institute of Advanced Jewish Studies at Bar Ilan University. From 2001 to 2003, he was a legal intern at Wine, Mishaiker & Ernstoff Law Offices in Jerusalem, Israel. Mr. Kidron holds an LL.B. and an International MBA from Bar Ilan University, Israel, and is a member of the Israel Bar Association. We believe that Mr. Kidron's qualifications to serve on our Board include his familiarity with the Company as its founder, his experience in capital markets, as well as his knowledge and familiarity with corporate management.
Source: Oramed Pharmaceuticals Inc. on 08/04/2016